🇺🇸 FDA
Pipeline program

Matching Placebo for TAK-279 Dose A, ZASOCITINIB, Matching Placebo for TAK-279 Dose B, ZASOCITINIB

TAK-279-PsA-3003

Phase 3 small_molecule active

Quick answer

Matching Placebo for TAK-279 Dose A, ZASOCITINIB, Matching Placebo for TAK-279 Dose B, ZASOCITINIB for Psoriatic Arthritis is a Phase 3 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).

Program details

Company
Takeda Pharmaceuticals International AG
Indication
Psoriatic Arthritis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials